Table 3.
Univariate and multivariate Cox regression analyses for overall survival.
| Variables | Comparison | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|---|
| H.R | 95% CI | P-value | H.R | 95% CI | P-value | ||
| Age, years | Increase per year | 0.96 | 0.93–0.99 | 0.009 | |||
| Sex | Male vs. Female | 1.064 | 0.51–2.11 | 0.915 | |||
| HBV | Yes vs. No | 0.78 | 0.42–0.14 | 0.427 | |||
| HCV | Yes vs No | 1.37 | 0.73–2.56 | 0.325 | |||
| Child-Pugh class | B vs A | 4.08 | 1.69–9.84 | 0.002 | 3.4 | 1.11–10.66 | 0.033 |
| BCLC stage | C vs B | 0.92 | 0.41–2.06 | 0.829 | |||
| EHM | Yes vs No | 0.75 | 0.41–1.37 | 0.349 | |||
| MVI | Yes vs No | 2.24 | 1.23–4.07 | 0.009 | |||
| AFP ≥ 200 ng/ml | Yes vs No | 2.03 | 1.13–3.68 | 0.019 | |||
| Disease control | Yes vs No | 0.24 | 0.1–0.57 | 0.001 | 0.18 | 0.07–0.46 | <0.001 |
| Combine treatment | Yes vs No | 0.16 | 0.04–0.68 | 0.013 | |||
| Post treatment | Yes vs No | 0.39 | 0.2–0.75 | 0.005 | 0.27 | 0.12–0.61 | 0.001 |
| Treatment option | Nivo vs. Rego | 1.1 | 0.6–2.01 | 0.763 | |||
AFP, alpha fetoprotein; BCLC, Barcellola Clinic Liver Cancer; CI, confidence interval; EHM; extra-hepatic metastasis; HBV, hepatitis B virus; HCV, hepatitis C virus; HR, hazard ratio; MVI, macro-vascular invasion.